Baxiva is developing the first K-antigen-targeting vaccine to prevent E. coli infections, offering the highest level of protection against UTIs and systemic infections.
| Website | https://www.baxiva.com |
| Employees | 10 (6 on RocketReach) |
| Founded | 2025 |
| Industry | Biotechnology Research |
Looking for a particular Baxiva employee's phone or email?
Baxiva Questions
Tim Keys is the CEO of Baxiva.
6 people are employed at Baxiva.
Baxiva is based in Schlieren, Zurich.
Top Baxiva Employees
-
Tim Keys
Chief Executive Officer at Baxiva
Switzerland1 -
Johannes Mühl
Chief Operating Officer at Baxiva
Zürich, ZH, CH -
1
-
Andrzej Sobieniecki
Research Associate at Baxiva
Zürich, ZH, CH -
Louise Larsson
Preclinical development lead at Baxiva
Stockholm County, Sweden1
G2Crowd Trusted
300K+
Plugin Users
